Establishment of a myelodysplastic syndrome (MDS)/secondary AML-derived T lymphoid cell line K2-MDS

Matsuda, Mitsuhiro; Maeda, Yasuhiro; Sumimoto, Yoshiyasu; Nawata, H; Sano, Tetsuaki; Higashishiba, Masaki; Haga, Hisae; Tatsumi, Yoichi; Horiuchi, Fusanari; Irimajiri, Kiyohiro; Kanamaru, Akihisa

doi:10.1016/s0145-2126(99)00168-x

Cited by 5 publications

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Firstly, the T‐LGL might arise from a clonally rearranged MDS stem cell and secondly, the T‐LGL could represent an autoimmune response to an antigen presented by normal or MDS marrow cells. Three reports suggest that T cells may arise from the MDS progenitor cell clones (Tsukamoto et al , 1993; Mongkonsritragoon et al , 1998; Matsuda et al , 2000). Because we did not determine the lineage involvement of the cytogenetic abnormalities seen in two of the patients with T‐LGL/MDS, the possibility that the T‐cell clone was derived from the MDS clone cannot be excluded.…”

Section: Discussionmentioning

confidence: 99%

Coincident myelodysplastic syndrome and T‐cell large granular lymphocytic disease: clinical and pathophysiological features

et al. 2001

View full text Add to dashboard Cite

Myelodysplastic syndrome (MDS) and T‐cell large granular lymphocytic disease (T‐LGL) are bone marrow failure disorders. Successful use of immunosuppressive agents to treat cytopenia in MDS and LGL suggests a common pathophysiology for the two conditions. Of 100 patients with initial diagnoses of either MDS or T‐LGL referred to the National Institutes of Health for immunosuppressive treatment of cytopenia, nine had characteristics of both T‐LGL and MDS (T‐LGL/MDS). Fifteen patients with T‐LGL received cyclosporin (CSA) (10 responses). Eight out of nine patients with T‐LGL/MDS received CSA (two responses) and one patient received ATG (one response). Of 76 patients with MDS, eight received CSA (one response) and 68 received ATG (21 responses). The response to immunosuppression was significantly lower in patients with T‐LGL/MDS and MDS than in patients with T‐LGL disease alone (28% vs. 66%, P = 0·01). The proportion of T‐helper cells and T‐suppressor cells with an activated phenotype (HLA‐DR+) was increased in patients with T‐LGL, T‐LGL/MDS and MDS, but the increase in activated T‐suppressor cells in patients with T‐LGL/MDS was not statistically significant. Autoreactive T cells may suppress haematopoiesis and contribute to the cytopenia in T‐LGL and some patients with MDS, leading to T‐LGL/MDS. The lower response rate of MDS or T‐LGL/MDS to immunosuppression, compared with T‐LGL alone, may reflect the older age and intrinsic stem cell abnormalities in MDS and T‐LGL/MDS patients.

show abstract

Section: Discussionmentioning

confidence: 99%